Hakutulokset - Gil Redelman‐Sidi

  • Näytetään 1 - 13 yhteensä 13 tuloksesta
Tarkenna hakua
  1. 1
    Could BCG be used to protect against COVID-19?

    Could BCG be used to protect against COVID-19? Tekijä Gil Redelman‐Sidi

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    BCG in Bladder Cancer Immunotherapy

    BCG in Bladder Cancer Immunotherapy Tekijä Song Jiang, Gil Redelman‐Sidi

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Rapidly Growing Mycobacteria Infection in Patients with Cancer

    Rapidly Growing Mycobacteria Infection in Patients with Cancer Tekijä Gil Redelman‐Sidi, Kent A. Sepkowitz

    Julkaistu 2010
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy

    Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy Tekijä Tommaso Morelli, Kohei Fujita, Gil Redelman‐Sidi, Paul Elkington

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells

    Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells Tekijä Gil Redelman‐Sidi, Gopa Iyer, David B. Solit, Michael S. Glickman

    Julkaistu 2013
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Mycobacteria exploit three genetically distinct DNA double‐strand break repair pathways

    Mycobacteria exploit three genetically distinct DNA double‐strand break repair pathways Tekijä Richa Gupta, Daniel Barkan, Gil Redelman‐Sidi, Stewart Shuman, Michael S. Glickman

    Julkaistu 2010
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling

    Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling Tekijä Anthony C. Antonelli, Anna Binyamin, Tobias M. Hohl, Michael S. Glickman, Gil Redelman‐Sidi

    Julkaistu 2020
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)

    ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune ch... Tekijä Gil Redelman‐Sidi, Olivier Michielin, Carlos Cervera, Camillo Ribi, José María Aguado, Mario Fernández‐Ruiz, Oriol Manuel

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer

    Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer Tekijä Tilly Varughese, Ying Taur, Nina Cohen, M. Lia Palomba, Susan K. Seo, Tobias M. Hohl, Gil Redelman‐Sidi

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

    The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma Tekijä María del Carmen López Castillo, Fabián Andrés Rosas Romero, Esther Argüello, Chrisann Kyi, Michael A. Postow, Gil Redelman‐Sidi

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    The Canonical Wnt Pathway Drives Macropinocytosis in Cancer

    The Canonical Wnt Pathway Drives Macropinocytosis in Cancer Tekijä Gil Redelman‐Sidi, Anna Binyamin, Isabella Gaeta, Wilhelm Palm, Craig B. Thompson, Paul B. Romesser, Scott W. Lowe, Mukta Bagul, John G. Doench, David E. Root, Michael S. Glickman

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Determinants of Severity in Cancer Patients with COVID-19 Illness

    Determinants of Severity in Cancer Patients with COVID-19 Illness Tekijä Elizabeth Robilotti, N. Esther Babady, Peter A. Mead, Thierry Rolling, Rocío Pérez-Johnston, Marilia Bernardes, Yael Bogler, Mario Caldararo, C. Ortiz, Michael S. Glickman, Alexa Joanow, Anna Kaltsas, Yeon Joo Lee, Anabella Lucca Bianchi, Amanda Mariano, Sejal Morjaria, Tamara Nawar, Genovefa A. Papanicolaou, Jacqueline Predmore, Gil Redelman‐Sidi, Elizabeth Schmidt, Susan K. Seo, Kent A. Sepkowitz, Monika K. Shah, Jedd D. Wolchok, Tobias M. Hohl, Ying Taur, Mini Kamboj

    Julkaistu 2020
    Hae kokoteksti
    Pré-impressão
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Determinants of COVID-19 disease severity in patients with cancer

    Determinants of COVID-19 disease severity in patients with cancer Tekijä Elizabeth Robilotti, N. Esther Babady, Peter A. Mead, Thierry Rolling, Rocío Pérez-Johnston, Marilia Bernardes, Yael Bogler, Mario Caldararo, Cesar J. Figueroa, Michael S. Glickman, Alexa Joanow, Anna Kaltsas, Yeon Joo Lee, Anabella Lucca Bianchi, Amanda Mariano, Sejal Morjaria, Tamara Nawar, Genovefa A. Papanicolaou, Jacqueline Predmore, Gil Redelman‐Sidi, Elizabeth Schmidt, Susan K. Seo, Kent A. Sepkowitz, Monika K. Shah, Jedd D. Wolchok, Tobias M. Hohl, Ying Taur, Mini Kamboj

    Julkaistu 2020
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: